X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (310) 310
oncology (262) 262
humans (247) 247
olaparib (243) 243
ovarian cancer (230) 230
olaparib maintenance therapy (205) 205
female (189) 189
poly polymerase (153) 153
cancer (143) 143
chemotherapy (126) 126
mutation (123) 123
ovarian neoplasms - drug therapy (112) 112
homologous recombination (103) 103
open-label (96) 96
breast cancer (94) 94
tumors (91) 91
dna repair (87) 87
parp inhibitor (84) 84
parp inhibitors (82) 82
ovarian neoplasms - genetics (78) 78
care and treatment (73) 73
maintenance therapy (66) 66
pharmacology & pharmacy (66) 66
poly polymerase inhibitors - therapeutic use (66) 66
antineoplastic agents - therapeutic use (64) 64
ovarian-cancer (62) 62
animals (61) 61
clinical trials (60) 60
deoxyribonucleic acid--dna (59) 59
dna damage (59) 59
double-blind (58) 58
breast-cancer (57) 57
brca (55) 55
fallopian-tube (55) 55
research (55) 55
cancer therapies (53) 53
brca1 protein - genetics (52) 52
middle aged (52) 52
monosaccharides (52) 52
sugars (52) 52
brca1 (50) 50
aged (48) 48
repair (47) 47
poly polymerase inhibitors - pharmacology (46) 46
adult (45) 45
brca2 protein - genetics (45) 45
health aspects (45) 45
patients (45) 45
ovarian neoplasms - pathology (44) 44
genetic aspects (43) 43
phthalazines - therapeutic use (43) 43
piperazines - therapeutic use (43) 43
endocrine system diseases (42) 42
medicine & public health (42) 42
obstetrics & gynecology (42) 42
pegylated liposomal doxorubicin (42) 42
poly polymerase inhibitors (41) 41
synthetic lethality (41) 41
antineoplastic agents - pharmacology (40) 40
review (40) 40
ribose (39) 39
recurrent epithelial ovarian (38) 38
therapy (38) 38
analysis (37) 37
dna-repair (37) 37
parp (37) 37
carcinoma (36) 36
dna-damage (36) 36
mutations (36) 36
negative breast-cancer (36) 36
bevacizumab (35) 35
cell line, tumor (35) 35
combination (35) 35
drug therapy (35) 35
genes, brca1 (35) 35
inhibitors (35) 35
molecular targeted therapy (35) 35
phthalazines - pharmacology (35) 35
piperazines - pharmacology (35) 35
women (35) 35
brca1 protein (34) 34
carcinoma, ovarian epithelial (34) 34
epithelial ovarian (34) 34
poly polymerases - metabolism (34) 34
somatic mutations (34) 34
brca2 (33) 33
platinum (33) 33
phase-i (32) 32
survival (32) 32
antineoplastic combined chemotherapy protocols - therapeutic use (31) 31
apoptosis (31) 31
multicenter (31) 31
biomarkers (30) 30
brca mutation (30) 30
male (30) 30
medical research (30) 30
polymerase (30) 30
brca2 mutations (29) 29
genes, brca2 (29) 29
germ-line mutation (29) 29
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


BMC Cancer, ISSN 1471-2407, 01/2019, Volume 19, Issue 1, pp. 44 - 44
BackgroundPoly (ADP-ribose) polymerase inhibitors (PARPi) have become the first targeted therapies available in the treatment of patients with high-grade... 
Ovarian Cancer | BRCA1/2 | Synthetic lethality | Chemoresistance | PARP inhibitor | DNA repair pathway | HOMOLOGOUS RECOMBINATION DEFICIENCY | MECHANISMS | BRCA1 | OLAPARIB | REPAIR | ONCOLOGY | RIBOSE POLYMERASE PARP | COMMON | INHIBITORS | Chemotherapy | Usage | Care and treatment | Patient outcomes | Genetic aspects | Ovarian cancer | Cancer | Health aspects | Sugars | Monosaccharides | Index Medicus
Journal Article
AAPS PharmSciTech, ISSN 1530-9932, 10/2019, Volume 20, Issue 7, pp. 1 - 13
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 09/2019, Volume 19, Issue 9, pp. 927 - 935
Introduction: The U.S. FDA has approved durvalumab for the treatment of advanced urothelial and non-small cell lung cancers. However, this immunotherapy agent... 
non-small cell lung cancer | urothelial carcinoma | Durvalumab | review | immunotherapy | CRITERIA | MEDICINE, RESEARCH & EXPERIMENTAL | HEAD | EFFICACY | SAFETY | IMMUNE CHECKPOINT INHIBITOR | MEDI4736 | OLAPARIB | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | Index Medicus
Journal Article
European journal of human genetics : EJHG, ISSN 1018-4813, 05/2019, Volume 27, Issue 9, pp. 1351 - 1360
BRCA testing received much publicity following Angelina Jolie's editorial "My Medical Choice" in May 2013 and updated NICE clinical guidance (CG164) in June... 
BREAST-CANCER | GLOBAL BURDEN | MORTALITY | OLAPARIB | GENETICS | BIOCHEMISTRY & MOLECULAR BIOLOGY | DISEASE | GENETICS & HEREDITY | RISK | OVARIAN-CANCER | HEALTH | INTERRUPTED TIME-SERIES | Statistical analysis | BRCA1 protein | Socio-economic aspects | Breast | Breast cancer | Patients | Catchment areas | Ovarian cancer | Index Medicus
Journal Article
Aktuelle Urologie, ISSN 0001-7868, 09/2019, Volume 50, Issue 5, pp. 509 - 512
Prostate cancer is the most common cancer in men. Its incidence increases with age. New treatment options have been introduced and there is a clear trend to... 
AR-V7 | next generation sequencing | FREE DNA | castration resistance | OLAPARIB MAINTENANCE THERAPY | CHEMOTHERAPY | mutation | RESISTANCE | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | Prostate cancer | ASSOCIATION | ABIRATERONE | BLOOD | ENZALUTAMIDE
Journal Article
Journal of Palliative Medicine, ISSN 1096-6218, 08/2019, Volume 22, Issue 8, pp. 977 - 980
Background: Chemotherapy-induced peripheral neuropathy is characterized by pain, numbness, and tingling in the hands and feet and by diminished quality of... 
Brief Reports | OXIDATIVE STRESS | PARP inhibitors | chemotherapy-induced peripheral neuropathy | PARP INHIBITION | MUTATION | HEALTH CARE SCIENCES & SERVICES | meta-analysis | DOUBLE-BLIND | SEROUS OVARIAN | VELIPARIB ABT-888 | OLAPARIB MAINTENANCE THERAPY | CANCER | Index Medicus
Journal Article
Journal of Bone Oncology, ISSN 2212-1374, 08/2019, Volume 17, p. 100246
Chondrosarcoma is a malignant tumor that arises from cartilaginous tissue and is radioresistant and chemoresistant to conventional treatments. The preferred... 
Carbon ions irradiation | Chondrosarcoma | Olaparib | Mutation status | PARP inhibitor
Journal Article
Expert Opinion on Drug Metabolism & Toxicology, ISSN 1742-5255, 07/2019, Volume 15, Issue 7, pp. 541 - 552
Journal Article
Cancer Biology & Therapy, ISSN 1538-4047, 07/2019, Volume 20, Issue 7, pp. 1035 - 1045
Pharmacological inhibition of PARP is a promising approach in treating high grade serous ovarian carcinoma (HGSOC). PARP inhibitors (PARPi) are most active in... 
targeted therapy | HSP90 inhibitor | PARP inhibitor | Ovarian cancer | GANETESPIB | AUTOPHAGY | TUMORS | BREAST-CANCER | OLAPARIB | REPAIR | ONCOLOGY | RESISTANCE | ATM
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 07/2019, Volume 30, Issue 6, pp. 554 - 561
Ovarian cancer is a heterogeneous disease with complex molecular and genetic hallmarks. Benefitting from profound understanding of molecular mechanisms in... 
POLY(ADP-RIBOSE) POLYMERASE | BRCA2 MUTATIONS | GRADE SEROUS OVARIAN | ovarian cancer | OPEN-LABEL | MAINTENANCE THERAPY | poly (ADP-ribose) polymerase inhibitor | PARP INHIBITOR | DNA damage repair | OLAPARIB | ONCOLOGY | DNA | PHARMACOLOGY & PHARMACY | HOMOLOGOUS RECOMBINATION | PHASE-I | Prevention | Care and treatment | Analysis | DNA damage | Cancer cells | Clinical trials | Research | Ovarian cancer
Journal Article
ONCOTARGETS AND THERAPY, ISSN 1178-6930, 2019, Volume 12, pp. 5177 - 5187
Approximately 5-10% of all patients diagnosed with breast cancer have germline BRCA1/2 mutations, which make their disease more susceptible to DNA-damaging... 
GERMLINE BRCA1/2 MUTATIONS | DNA-DAMAGE | PLATINUM | breast cancer | BRCA mutation | MAINTENANCE THERAPY | OVARIAN-CARCINOMA | BIOMARKERS | OLAPARIB | REPAIR | ONCOLOGY | homologous recombination deficiency | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | RUCAPARIB | talazoparib | INHIBITOR | Talazoparib
Journal Article